Education
About Us
Working with TipRanks
Follow Us
Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
Total Valuation
Kalaris Therapeutics has a market cap or net worth of $97.58M. The enterprise value is -$28.55M.
Market Cap$97.58M
Enterprise Value-$28.55M
Share Statistics
Kalaris Therapeutics has 18,702,414 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,702,414
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kalaris Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count14
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Kalaris Therapeutics is ―. Kalaris Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Kalaris Therapeutics had revenue of ― and earned ― in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income―
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Kalaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.03
52-Week Price Change-68.57%
50-Day Moving Average8.42
200-Day Moving Average13.21
Relative Strength Index (RSI)33.37
Average Volume (3m)49.38K
Important Dates
Kalaris Therapeutics upcoming earnings date is Oct 31, 2024, TBA Not Confirmed.
Last Earnings DateAug 1, 2024
Next Earnings DateOct 31, 2024
Ex-Dividend Date―
Financial Position
Kalaris Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Kalaris Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Kalaris Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Kalaris Therapeutics has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Kalaris Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.00
Price Target Upside260.21% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast72.12%